A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Running, not enrolling · Phase 1/Phase 2
Conditions studied: Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Leukemia
In brief
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. This study consists of Phase 1 dose-exploration cohorts, Phase 1 dose-expansion cohort(s), a Phase 1 pediatric cohort (will enroll patients ages 1 to \< 12 years), and a Phase 2 cohort.
Key facts
- Study ID
- NCT05885464
- Run by
- Beam Therapeutics Inc.
- People needed
- 5
- Starts
- 2023-05-25
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2025-01-13
Who can join
Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
- Colorado Blood Cancer Institute — Denver, Colorado, United States
- University of Chicago — Chicago, Illinois, United States
- The University of Kansas Cancer Center — Fairway, Kansas, United States
- Dana Farber and Boston Children's Hospital — Boston, Massachusetts, United States
- Cleveland Clinic- Taussig Cancer Center — Cleveland, Ohio, United States
- OHSU Knight Cancer Institute Hematology Oncology — Portland, Oregon, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Sarah Cannon- TriStar Bone Marrow Transplant — Nashville, Tennessee, United States
- Methodist Hospital - Texas Transplant Institute — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.